Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma.

[1]  D. Polsky,et al.  Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples. , 2019, The Journal of molecular diagnostics : JMD.

[2]  D. Schadendorf,et al.  Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? , 2018, The Lancet. Oncology.

[3]  B. Chabner,et al.  Application of Cell-free DNA Analysis to Cancer Treatment. , 2018, The New England journal of medicine.

[4]  Joel Pel,et al.  Rapid and highly-specific generation of targeted DNA sequencing libraries enabled by linking capture probes with universal primers , 2018, bioRxiv.

[5]  E. Lipson,et al.  From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting , 2018, Molecular oncology.

[6]  Doron Lipson,et al.  Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA , 2018, The Journal of molecular diagnostics : JMD.

[7]  J. C. Love,et al.  Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma , 2018, Nature Communications.

[8]  C. Paweletz,et al.  False-Positive Plasma Genotyping Due to Clonal Hematopoiesis , 2018, Clinical Cancer Research.

[9]  Sarah Wordsworth,et al.  Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature , 2018, Genetics in medicine : official journal of the American College of Medical Genetics.

[10]  K. Walsh,et al.  Somatic Mutations and Clonal Hematopoiesis: Unexpected Potential New Drivers of Age-Related Cardiovascular Disease , 2018, Circulation research.

[11]  A. Vincent-Salomon,et al.  Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. , 2018, Clinical chemistry.

[12]  R. Levine,et al.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. , 2018, Cell stem cell.

[13]  P. Mundra,et al.  Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients , 2018, European journal of cancer.

[14]  C. Hyland,et al.  Non-invasive fetal RHD genotyping for RhD negative women stratified into RHD gene deletion or variant groups: comparative accuracy using two blood collection tube types. , 2017, Pathology.

[15]  Ash A. Alizadeh,et al.  Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. , 2017, Cancer Discovery.

[16]  N. Dhomen,et al.  Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Millward,et al.  Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. , 2017, Cancer letters.

[18]  M. Huibers,et al.  Preanalytical blood sample workup for cell‐free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics , 2017, Cancer medicine.

[19]  U. Lehmann,et al.  Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection. , 2017, The Journal of molecular diagnostics : JMD.

[20]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[21]  P. Jänne,et al.  Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  M. Cowley,et al.  Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma , 2017, Molecular Diagnosis & Therapy.

[23]  G. Mann,et al.  Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Amar S Basu,et al.  Digital Assays Part I: Partitioning Statistics and Digital PCR , 2017, SLAS technology.

[25]  Winnie S. Liang,et al.  Evaluation of pre-analytical factors affecting plasma DNA analysis , 2017, bioRxiv.

[26]  Jing Sun,et al.  Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types , 2017, Scientific Reports.

[27]  Ryan E. Mills,et al.  Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy , 2017, Oncotarget.

[28]  V. Chiarion-Sileni,et al.  Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab , 2016, Oncoimmunology.

[29]  K. Dobbin,et al.  Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations , 2016, Journal of Immunotherapy for Cancer.

[30]  K. Dobbin,et al.  Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation , 2016, Journal of Immunotherapy for Cancer.

[31]  V. Velculescu,et al.  The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA , 2016, Clinical Cancer Research.

[32]  P. B. Gahan,et al.  Origins, structures, and functions of circulating DNA in oncology , 2016, Cancer and Metastasis Reviews.

[33]  Noah C Welker,et al.  Fragment Length of Circulating Tumor DNA , 2016, PLoS genetics.

[34]  C. Berking,et al.  Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.

[35]  L. Postovit,et al.  A Digital PCR-Based Method for Efficient and Highly Specific Screening of Genome Edited Cells , 2016, PloS one.

[36]  A. Karsan,et al.  Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay. , 2016, The Journal of molecular diagnostics : JMD.

[37]  A. Kohlmann,et al.  Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) , 2016, PloS one.

[38]  J. Larkin,et al.  Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma , 2016, British Journal of Cancer.

[39]  Matthew W. Snyder,et al.  Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin , 2016, Cell.

[40]  J. Wilmott,et al.  Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors , 2015, Cancer.

[41]  A. Hauschild,et al.  Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials , 2015, Clinical Cancer Research.

[42]  T. H. Santa Rita,et al.  EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. , 2015, Clinical biochemistry.

[43]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[44]  Drew M Pardoll,et al.  Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade , 2014, Journal of Immunotherapy for Cancer.

[45]  D. Schadendorf,et al.  TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. , 2014, Journal of the National Cancer Institute.

[46]  D. Link,et al.  Determining lower limits of detection of digital PCR assays for cancer-related gene mutations , 2014, Biomolecular detection and quantification.

[47]  Alison S. Devonshire,et al.  Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification , 2014, Analytical and Bioanalytical Chemistry.

[48]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[49]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[50]  C. Paweletz,et al.  Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.

[51]  T. Dingle,et al.  Tolerance of droplet-digital PCR vs real-time quantitative PCR to inhibitory substances. , 2013, Clinical chemistry.

[52]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[53]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[54]  M. Baker.  Digital PCR hits its stride , 2012, Nature Methods.

[55]  A. Richardson,et al.  BEAMing Up Personalized Medicine: Mutation Detection in Blood , 2012, Clinical Cancer Research.

[56]  Lauren E Haydu,et al.  Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.

[57]  R. Stokowski,et al.  Influence of Temperature during Transportation on Cell-Free DNA Analysis , 2012, Fetal Diagnosis and Therapy.

[58]  Jeff Mellen,et al.  High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number , 2011, Analytical chemistry.

[59]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[61]  M. Weichenthal,et al.  Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse , 2009, Melanoma research.

[62]  D. Armbruster,et al.  Limit of blank, limit of detection and limit of quantitation. , 2008, The Clinical biochemist. Reviews.

[63]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[64]  Frank Diehl,et al.  Detection and quantification of mutations in the plasma of patients with colorectal tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Tania Nolan,et al.  Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. , 2004, Journal of biomolecular techniques : JBT.

[66]  L. Poon,et al.  Clinical Chemistry 47:9 1607–1613 (2001) Molecular Diagnostics and Genetics Effects of Blood-Processing Protocols on Fetal and Total DNA Quantification in Maternal Plasma , 2001 .

[67]  M. Busch,et al.  Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma , 2001, Transfusion.

[68]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[69]  P Mandel,et al.  Les acides nucleiques du plasma sanguin chez l' homme , 1948 .

[70]  Leonardo Pinheiro,et al.  Basic Concepts and Validation of Digital PCR Measurements. , 2018, Methods in molecular biology.

[71]  MA Katharina Schwarze BSc,et al.  Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature , 2018, Genetics in Medicine.

[72]  P. Pauwels,et al.  A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma. , 2017, The Journal of molecular diagnostics : JMD.

[73]  P. Chapman,et al.  Systemic Therapy Options for Patients With Unresectable Melanoma. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[74]  R. Zárate,et al.  Quantitative Cell-Free Circulating BRAF Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors , 2014 .

[75]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[76]  R. Chiu,et al.  EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. , 2004, Clinical chemistry.

[77]  Y. Lo,et al.  Rapid clearance of fetal DNA from maternal plasma. , 1999, American journal of human genetics.